ライフサイエンスコーパス: risperidone

1 luoxetine combination (OFC), quetiapine, and risperidone.

2 ponse after 3 weeks received open adjunctive risperidone.

3 e observed for aripiprazole, olanzapine, and risperidone.

4 e observed for aripiprazole, olanzapine, and risperidone.

5 piprazole, and parent training combined with risperidone.

6 SD 0.6) for cariprazine and 3.8 mg (0.4) for risperidone.

7 lanzapine, 0.33 for quetiapine, and 0.32 for risperidone.

8 apine, 506 mg for quetiapine, and 2.4 mg for risperidone.

9 lanzapine, 0.34 for quetiapine, and 0.22 for risperidone.

10 215) for quetiapine, and 2.4 mg (SD=1.0) for risperidone.

11 on, particularly the atypical antipsychotic, risperidone.

12 lanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.

13 curred in all patients but was resolved with risperidone.

14 s compared with those receiving inositol and risperidone.

15 augmentation with lamotrigine, inositol, and risperidone.

16 .5-25.3) versus 26.7 (95% CI=25.2-28.2) with risperidone.

17 orms of the h5-HT7 receptor exposed to 20 nM risperidone.

18 lozapine than for olanzapine, quetiapine, or risperidone.

19 augmentation with lamotrigine, inositol, or risperidone.

20 demonstrate the same anomalous properties as risperidone.

21 were coadministered with haloperidol and/or risperidone.

22 e, total cholesterol, and triglycerides than risperidone.

23 than clozapine, haloperidol, olanzapine, and risperidone.

24 e long-acting injectable risperidone or oral risperidone.

25 iprazine and 131 (57%) patients treated with risperidone.

26 rtality risk for olanzapine, quetiapine, and risperidone.

27 ipiprazole and 13 patients were treated with risperidone.

28 ibitor bupropion and the dopamine antagonist risperidone.

29 uring 7-day bupropion (0.32-1.8 mg/kg/h) and risperidone (0.001-0.0056 mg/kg/h) treatment periods.

30 e effects of the atypical antipsychotic drug risperidone (0.1 mg/kg) on DA, but not ACh, efflux in th

31 -20 mg/day), quetiapine (100-800 mg/day), or risperidone (0.5-4 mg/day) administered in twice-daily d

32 -20 mg/day), quetiapine (100-800 mg/day), or risperidone (0.5-4 mg/day).

33 ment with either olanzapine (2.5-20 mg/day), risperidone (0.5-6 mg/day), or molindone (10-140 mg/day,

34 2), ziprasidone (-0.25, -0.48 to -0.01), and risperidone (-0.14, -0.27 to -0.01) were significantly m

35 /kg vehicle) or three sham groups (4.5 mg/kg risperidone, 0.5 mg/kg haloperidol, or 1 mL/kg vehicle).

36 roups (0.045 mg/kg, 0.45 mg/kg, or 4.5 mg/kg risperidone; 0.5 mg/kg haloperidol; or 1 mL/kg vehicle)

37 treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).

38 eek of treatment with the antipsychotic drug risperidone (1-week post-treatment).

39 SB-399885 potentiated risperidone (1.0 mg/kg)-induced DA efflux in both region

40 usted mortality risk was increased with both risperidone (1.7%; 95% CI, 0.6%-2.8%; P = .003) and olan

41 , patients were randomly assigned to receive risperidone, 1 mg/d, or placebo for 6 weeks.

42 y [N=66]; quetiapine, 200-800 mg/day [N=63]; risperidone, 1.5-6.0 mg/day [N=69]; or ziprasidone, 40-1

43 olanzapine=144, placebo=75, quetiapine=125, risperidone=124, UC=30 and ziprasidone=32), 4 of which w

44 , 40 or 80 mg twice daily (BID), placebo, or risperidone, 2 mg BID, for up to 6 weeks.

45 efficacy favored olanzapine (22.1 weeks) and risperidone (26.7 weeks) as compared with quetiapine (9.

46 g, 4.5 mg [target dose], or 6 mg per day) or risperidone (3 mg, 4 mg [target dose], or 6 mg per day);

47 th an NNH of 26 (95% CI, 15-99); followed by risperidone, 3.7% (95% CI, 2.2%-5.3%; P < .01) with an N

48 eficits reoccurred after daily treatments of risperidone (4.5 mg/kg) and haloperidol (p < .05).

49 onse rates (molindone: 50%; olanzapine: 34%; risperidone: 46%) or magnitude of symptom reduction.

50 o treatment (230 for cariprazine and 231 for risperidone); 460 were included in the safety population

51 than in the group that continued to receive risperidone (48% [13 of 27 patients in group 2] vs. 15%

52 n olanzapine (43.7%, 95% CI=28.8%-58.6%) and risperidone (54.3%, 95% CI=39.9%-68.7%).

53 for placebo, 79% from baseline; 7 [4-14] for risperidone, 58% from baseline; 6.5 [5-14] for haloperid

54 ved placebo than in the groups that received risperidone (60% [24 of 40 patients in group 3] vs. 33%

55 PANSS-FSNS from baseline to week 26 than did risperidone (-8.90 points for cariprazine vs -7.44 point

56 5-HT(7)) receptor-inactivating properties of risperidone, 9-OH-risperidone, bromocriptine, methiothep

57 As in the recombinant cell line, risperidone, 9-OH-risperidone, methiothepin, and bromocr

58 idated for polymeric microspheres containing risperidone (a practically water insoluble small molecul

59 The atypical antipsychotic drug risperidone, a multireceptor antagonist, which lacks 5-H

60 Long-acting injectable risperidone, a second-generation antipsychotic agent, ma

61 The use of long-acting injectable risperidone after a first episode of schizophrenia has n

62 Olanzapine, quetiapine, and risperidone all produced significant improvements in neu

63 dition, treatment with the FDA-approved drug risperidone ameliorates the targeted repetitive behavior

64 Risperidone, amisulpride, and valproate did not influenc

65 pical, first-generation antipsychotic drug), risperidone (an atypical, second-generation antipsychoti

66 verity scores were 1.4 (95% CI=1.2-1.6) with risperidone and 1.2 (95% CI=1.0-1.4) with olanzapine.

67 268 patients), 81% (111 of 137) who received risperidone and 87.8% (115 of 131) who received placebo

68 f elevation in plasma prolactin levels (with risperidone and 9-hydroxyrisperidone being exceptions),

69 comparing the long-acting injectable vs oral risperidone and cognitive remediation vs healthy-behavio

70 e acute administration of the combination of risperidone and DVX.

71 hat although single or multiple low doses of risperidone and haloperidol may be innocuous to subseque

72 e P450 enzymes, responsible for metabolizing risperidone and haloperidol, the possibility that the au

73 5-HT7-inactivating properties, and only 9-OH-risperidone and methiothepin were found to demonstrate t

74 Risperidone and olanzapine did not demonstrate superior

75 The results show that both risperidone and olanzapine significantly improved perfor

76 ed treatment with an atypical antipsychotic, risperidone and olanzapine were more effective than quet

77 Young adult male rats were treated with risperidone and paliperidone, atypical antipsychotic med

78 Adding EX/RP to SRIs was superior to both risperidone and pill placebo.

79 Adding EX/RP was also superior to risperidone and placebo in improving insight, functionin

80 ptoms (NNH = 10 for olanzapine; NNH = 20 for risperidone), and urinary tract symptoms (NNH range = 16

81 core decrease >/=25%: 80% for EX/RP, 23% for risperidone, and 15% for placebo; P < .001).

82 for olanzapine, 2.46 (95% CI, 1.94-3.12) for risperidone, and 2.16 (95% CI, 1.88-2.48) for quetiapine

83 d to quetiapine, 29% of patients assigned to risperidone, and 21% of patients assigned to placebo (P=

84 (Y-BOCS score </=12: 43% for EX/RP, 13% for risperidone, and 5% for placebo; P = .001).

85 ved quetiapine, 18% of patients who received risperidone, and 5% of patients who received placebo dis

86 quetiapine, 74 percent of those assigned to risperidone, and 79 percent of those assigned to ziprasi

87 Aripiprazole, risperidone, and amisulpride increased P50 suppression i

88 ntadine, selegiline, olanzapine, quetiapine, risperidone, and citalopram do not appear to be effectiv

89 action of antipsychotic drugs, particularly risperidone, and further highlight the promise of optimi

90 ofiles of methylphenidate, aripiprazole, and risperidone, and of kinase drugs targeting the VEGF rece

91 ntipsychotic drugs, specifically quetiapine, risperidone, and olanzapine, are known to cause acute ki

92 ss akathisia than haloperidol, aripiprazole, risperidone, and olanzapine, but, again, evidence was ve

93 etes may be attributed to use of olanzapine, risperidone, and quetiapine in patients taking these med

94 ole, chlorpromazine, quetiapine, olanzapine, risperidone, and ziprasidone all potently antagonize the

95 blind study compared olanzapine, quetiapine, risperidone, and ziprasidone in patients who had just di

96 Quetiapine, risperidone, and ziprasidone use were not associated wit

97 s), e.g., clozapine, quetiapine, olanzapine, risperidone, and ziprasidone, have been reported to pref

98 eridone, lurasidone, olanzapine, quetiapine, risperidone, and ziprasidone.

99 th different solubility profiles compared to risperidone; and 2) to determine whether release charact

100 l, these negative results with bupropion and risperidone are concordant with previous human laborator

101 (eg, clozapine, olanzapine, quetiapine, and risperidone) are associated with an increased risk of we

102 bility that highly prescribed drugs, such as risperidone, are irreversibly antagonizing GPCR function

103 icantly improved with long-acting injectable risperidone as compared with control treatments.

104 (+/-SE) HRSD-17 scores improved more in the risperidone augmentation group than in the placebo group

105 Risperidone augmentation produced a statistically signif

106 zide), leukaemia (alvocidib), schizophrenia (risperidone, belaperidone), malaria (mefloquine) and nic

107 Long-acting injectable risperidone better controlled mean levels of hallucinati

108 inactivating properties of risperidone, 9-OH-risperidone, bromocriptine, methiothepin, metergoline, a

109 than in patients treated with quetiapine or risperidone but not olanzapine.

110 ce were cataleptic following haloperidol and risperidone, but did not respond to clozapine's locomoto

111 In sum, we confirm that haloperidol and risperidone caused catalepsy in rodents, driven by stron

112 Risperidone caused greater in vitro block of the alterna

113 her risk of relapse after discontinuation of risperidone compared with continued risperidone treatmen

114 (N=52) showed a better treatment response to risperidone compared with other drugs, but this associat

115 ed improvement in symptoms when treated with risperidone compared with patients with fast metabolizer

116 I-resistant symptoms, 6-month treatment with risperidone compared with placebo did not reduce PTSD sy

117 Olanzapine, quetiapine, and risperidone demonstrated comparable effectiveness in ear

118 Treatment response to risperidone did not appear to depend upon these patient

119 Adherence to oral risperidone did not appear to differ before randomizatio

120 Risperidone did not reduce symptoms of depression (MADRS

121 Patients receiving risperidone did not significantly differ from those rece

122 Risperidone displays a novel mechanism of antagonism of

123 r quetiapine (dose range: 200-800 mg/day) or risperidone (dose range: 2-8 mg/day) for an 8-week perio

124 hours (42%), and weight gain (40%); and for risperidone, drowsiness (50%), menstrual irregularities

125 ion to 25 to 50 mg of long-acting injectable risperidone every two weeks or to a psychiatrist's choic

126 ed to harm [NNH] = 87), stroke (NNH = 53 for risperidone), extrapyramidal symptoms (NNH = 10 for olan

127 Pretreatment of the cells with 5 or 20 nM risperidone, followed by removal of the drug from the me

128 ith aripiprazole, olanzapine, quetiapine, or risperidone for 12 weeks.

129 ntinue risperidone for 32 weeks, to continue risperidone for 16 weeks followed by switch to placebo f

130 ntinue risperidone for 32 weeks, to continue risperidone for 16 weeks followed by switch to placebo f

131 of agitation or psychosis were treated with risperidone for 16 weeks, after which patients who respo

132 of agitation or psychosis were treated with risperidone for 16 weeks, after which patients who respo

133 ggression received open-label treatment with risperidone for 16 weeks.

134 d (N=110) were randomly assigned to continue risperidone for 32 weeks, to continue risperidone for 16

135 d (N=110) were randomly assigned to continue risperidone for 32 weeks, to continue risperidone for 16

136 te, patients with FEP were treated with oral risperidone for 4 weeks at an initial dose of 1 mg/day t

137 Olanzapine was superior to haloperidol and risperidone for reduction of negative symptoms.

138 ive treatment with lamotrigine, inositol, or risperidone for up to 16 weeks.

139 apine, perphenazine, quetiapine fumarate, or risperidone for up to 18 months as reported previously b

140 rpromazine, haloperidol, trifluoperazine, or risperidone) for 12 months or to switch their medication

141 roup (40.9%, 95% CI=16.8%-65.0%) than in the risperidone group (18.9%, 95% CI=0%-39.2%) had subsequen

142 t 52 weeks or withdrawal from study) and the risperidone group (at 12 weeks).

143 on in the oral group than in the long-acting risperidone group (chi21 = 6.1; P = .01).

144 r relapse rate was lower for the long-acting risperidone group compared with the oral group (5% vs 33

145 omization but was better for the long-acting risperidone group compared with the oral group (t80 = 5.

146 One patient in the risperidone group died of a cause regarded as unrelated

147 CAPS scores from baseline to 24 weeks in the risperidone group was -16.3 (95% CI, -19.7 to -12.9) and

148 e group and 229 (99%) of 230 patients in the risperidone group were included in the modified intentio

149 used treatment in the long-acting injectable risperidone group.

150 erphenazine group than in the olanzapine and risperidone groups.

151 Molindone was superior to risperidone, haloperidol, and olanzapine in terms of wei

152 l antipsychotic drugs, such as clozapine and risperidone, have a high affinity for the serotonin 5-HT

153 , 95% confidence interval (CI): 1.22, 2.19), risperidone (HR = 1.60, 95% CI: 1.19, 2.14), or quetiapi

154 otics (HR = 2.89 [95% CI = 1.64-5.10]) or to risperidone (HR = 2.20 [95% CI = 1.14-4.26]).

155 lamotrigine may be superior to inositol and risperidone in improving treatment-resistant bipolar dep

156 uation rates) of olanzapine, quetiapine, and risperidone in patients early in the course of psychotic

157 nth treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia

158 ine in terms of weight gain, and superior to risperidone in terms of increase in prolactin release.

159 published showing effectiveness of low-dose risperidone in the management of behaviour problems as c

160 As in the recombinant cell line, exposure of risperidone-inactivated astrocyte r5-HT receptors to com

161 ITI-007 (60 mg and 120 mg), placebo, and risperidone, included for assay sensitivity, were evalua

162 bute to the potentiation of haloperidol- and risperidone-induced DA efflux in the mPFC or HIP.

163 As compared with a reference group of risperidone initiators, the risk was higher among those

164 ll radioligand binding studies indicate that risperidone interacts in an irreversible or pseudo-irrev

165 cologic agents (dexamethasone, rivastigmine, risperidone, ketamine, dexmedetomidine, propofol, and cl

166 peridone, risperidone long-acting injection (risperidone LAI), and ziprasidone--were used to identify

167 0 points for cariprazine vs -7.44 points for risperidone; least squares mean difference -1.46, 95% CI

168 A critical difference between naltrexone and risperidone loaded microspheres is their respective bi-p

169 pine, paliperidone, quetiapine, risperidone, risperidone long-acting injection (risperidone LAI), and

170 ogical treatment (valproic acid, fluoxetine, risperidone, lorazepam).

171 A total of 180 patients received open-label risperidone (mean dose, 0.97 mg daily).

172 y), quetiapine (mean dose, 56.5 mg per day), risperidone (mean dose, 1.0 mg per day), or placebo.

173 lowed by haloperidol (mean=65.5%, SD=40.3%), risperidone (mean=49.2%, SD=33.9%), and quetiapine (mean

174 OCS scores based on mixed-effects models (vs risperidone: mean [SE], -9.72 [1.38]; P < .001 vs placeb

175 wed no significant difference in CAPS score (risperidone: mean, 64.43; 95% CI, 61.98 to 66.89, vs pla

176 8.1 weeks), quetiapine (median, 5.3 weeks), risperidone (median, 7.4 weeks), and placebo (median, 8.

177 nuation was longer for patients treated with risperidone (median: 7.0 months) and olanzapine (6.3 mon

178 months) than for quetiapine (median=3.3), or risperidone (median=2.8), but not for olanzapine (median

179 the recombinant cell line, risperidone, 9-OH-risperidone, methiothepin, and bromocriptine were found

180 In vivo pharmacokinetic profiles of the risperidone microsphere formulations following intramusc

181 validated for the compositionally equivalent risperidone microspheres based on the in vitro release d

182 In vitro release of the risperidone microspheres was investigated using differen

183 g processes were investigated to produce the risperidone microspheres with similar drug loading (appr

184 t Risperdal(R) Consta(R) was used to prepare risperidone microspheres.

185 suggest that the apparent adverse effect of risperidone might result from treatment-related changes

186 n this study to explore the effect of 8-week risperidone monotherapy on NAA.

187 ith schizophrenia treated with quetiapine or risperidone monotherapy were randomized to 12 weeks of p

188 (FESP) at baseline and then after 8-weeks of risperidone monotherapy, and compared the findings to 38

189 36), by 5.3 kg (95% CI, 4.8 to 5.9 kg) with risperidone (n = 135), and by 4.4 kg (95% CI, 3.7 to 5.2

190 h olanzapine (N=133), quetiapine (N=134), or risperidone (N=133).

191 seline antipsychotic was olanzapine (N=319), risperidone (N=271), or quetiapine (N=94), the authors e

192 ived either single doses of aripiprazole and risperidone (n=28), amisulpride and lorazepam (n=30), or

193 ere randomly assigned to haloperidol (n=28), risperidone (n=29), or placebo (n=29).

194 gned to treatment with olanzapine (N=314) or risperidone (N=321), the authors assessed the impact of

195 al (olanzapine [N=19], quetiapine [N=15], or risperidone [N=16]).

196 163 who were eligible, 100 were randomized (risperidone, n = 40; EX/RP, n = 40; and placebo, n = 20)

197 Compared with risperidone, newer antipsychotics were not associated wi

198 apine (odds ratio: 1.82, 95% CI: 1.61-2.05), risperidone (odds ratio: 1.53, 95% CI: 1.43-1.64), queti

199 antipsychotic drugs (APDs), e.g. clozapine, risperidone, olanzapine and ziprasidone, to improve cogn

200 icipated in an 8 week, double-blind study of risperidone, olanzapine, and haloperidol.

201 There were 32 studies comprising 66 risperidone, olanzapine, quetiapine, and ziprasidone arm

202 paring an atypical antipsychotic medication (risperidone, olanzapine, quetiapine, aripiprazole, zipra

203 outpatient treatment with an antipsychotic (risperidone, olanzapine, quetiapine, or haloperidol) or

204 l antipsychotics olanzapine, quetiapine, and risperidone on cognition in patients with Alzheimer's di

205 e the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in patients with

206 le (BPRS) hostile suspiciousness factor, and risperidone on the BPRS psychosis factor.

207 Global Impression of Changes, olanzapine and risperidone on the Brief Psychiatric Rating Scale (BPRS)

208 the Neuropsychiatric Inventory total score, risperidone on the Clinical Global Impression of Changes

209 howed greater improvement with olanzapine or risperidone on the Neuropsychiatric Inventory total scor

210 Patients were treated with oral risperidone (open label) for 4 weeks with dosages that w

211 gain after 12 weeks of treatment with either risperidone or aripiprazole in a double-blind randomized

212 and after 12 weeks of treatment with either risperidone or aripiprazole.

213 DG in the same animal, paliperidone, but not risperidone or fluoxetine (0.6 mg/kg/day) resulted in in

214 Adult rats were given either risperidone or olanzapine in their drinking water for 21

215 to receive 16 weeks of treatment with either risperidone or olanzapine.

216 randomized to receive long-acting injectable risperidone or oral risperidone.

217 medicated patients with schizophrenia taking risperidone or paliperidone by regular intramuscular inj

218 e (OR, 1.53, 95% CI, 1.17-2.0; NNT, 10), and risperidone (OR, 1.83, 95% CI, 1.16-2.88; NNT, 8).

219 uetiapine (OR, 1.79; 95% CI, 1.33-2.42), and risperidone (OR, 2.37; 95% CI, 1.31-4.30).

220 -dose treatment with olanzapine, quetiapine, risperidone, or placebo for up to 36 weeks.

221 atment with olanzapine, quetiapine fumarate, risperidone, or placebo with the option of double-blind

222 asked, flexible-dose olanzapine, quetiapine, risperidone, or placebo.

223 n 10% during less than 1 year of olanzapine, risperidone, or quetiapine therapy.

224 eceive olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone for up to 18 months.

225 inued treatment with olanzapine, quetiapine, risperidone, or ziprasidone in phase 1 or 1B of the tria

226 d-generation drugs (olanzapine, quetia-pine, risperidone, or ziprasidone) and followed for up to 18 m

227 I-007 60 mg (p = .017, effect size = .4) and risperidone (p = .013, effect size = .4) demonstrated an

228 001), 0.18 for quetiapine (P<.001), 0.26 for risperidone (P<.001), and 0.12 for ziprasidone (P<.06),

229 compared with 10 of 26 (38.5%) who continued risperidone (p<0.02).

230 ne group than in the quetiapine (P<0.001) or risperidone (P=0.002) group, but not in the perphenazine

231 5, or 50 mg) added to ongoing treatment with risperidone, paliperidone, or aripiprazole.

232 ion of the combination of DVX, 50 mg/kg, and risperidone, produced significantly greater increases in

233 67 patients who initiated use of olanzapine, risperidone, quetiapine, or haloperidol in 1999-2001 aft

234 More risperidone recipients than placebo recipients experienc

235 Headache (8.8% of risperidone recipients vs. 14.5% of placebo recipients),

236 fidence interval [CI]=1.38-1.73) followed by risperidone (reference), olanzapine (relative risk=0.99,

237 cinations, 13 of 17 (76.5%) who discontinued risperidone relapsed, compared with 10 of 26 (38.5%) who

238 Patients who received long-acting injectable risperidone reported more adverse events at the injectio

239 in the risk for malformations observed with risperidone requires additional study.

240 %, and 71.4% for olanzapine, quetiapine, and risperidone, respectively.

241 hort-term treatment with both quetiapine and risperidone resulted in improvements in social competenc

242 Ps: chlorpromazine (CLP), haloperidol (HAL), risperidone (RIS) and clozapine (CLZ), at concentrations

243 idone, olanzapine, paliperidone, quetiapine, risperidone, risperidone long-acting injection (risperid

244 ngle trial-based superiority, and except for risperidone's superiority at 3 and 6 months when requiri

245 Thus, risperidone seems to be producing a rapid, long-lasting

246 Olanzapine and risperidone showed declining rates and quetiapine showed

247 antipsychotics (olanzapine, quetiapine, and risperidone) showed a dose-response increase in mortalit

248 (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).

249 ignificant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and

250 patients who received long-acting injectable risperidone than among those who received oral antipsych

251 (RR, 1.26; 95% CI, 0.88-1.81) was found for risperidone that was independent of measured confounders

252 ight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative

253 risperidone therapy for 32 weeks (group 1), risperidone therapy for 16 weeks followed by placebo for

254 fashion, to one of three regimens: continued risperidone therapy for 32 weeks (group 1), risperidone

255 psychosis or agitation that had responded to risperidone therapy for 4 to 8 months, discontinuation o

256 Those who had a response to risperidone therapy were then randomly assigned, in a do

257 hotic use (i.e., olanzapine, quetiapine, and risperidone) throughout the 36-week trial, using logisti

258 of switching from olanzapine, quetiapine, or risperidone to aripiprazole to ameliorate metabolic risk

259 e ability of the atypical APDs clozapine and risperidone to increase DA but not ACh efflux in the mPF

260 s higher in the group that was switched from risperidone to placebo than in the group that continued

261 n the first of two studies, paliperidone and risperidone treatment (at 1mg/kg/day) resulted in increa

262 After 6 weeks of risperidone treatment and significant clinical improveme

263 Risperidone treatment exacerbated these deficits, perhap

264 However, fluoxetine, but not paliperidone or risperidone treatment increased BrdU positive cells in t

265 Risperidone treatment increased methamphetamine choice,

266 This is the first evidence that short-term risperidone treatment induces an acute reduction of MPFC

267 antipsychotic-naive SCZ patients with 8-week risperidone treatment to evaluate the association betwee

268 ation of risperidone compared with continued risperidone treatment.

269 ight gain particularly being associated with risperidone treatment.

270 ny drug treatment and again after 6 weeks of risperidone treatment.

271 With risperidone, triglycerides increased significantly (mean

272 Risperidone (up to 4 mg once daily) or placebo.

273 ere randomized to the addition of 8 weeks of risperidone (up to 4 mg/d), EX/RP (17 sessions delivered

274 ic (haloperidol, olanzapine, quetiapine, and risperidone), valproic acid and its derivatives, or an a

275 Adverse events were more common with risperidone vs placebo, including self-reported weight g

276 IP, but not the mPFC, DA efflux by 0.3 mg/kg risperidone was also potentiated by SB-399885, 3 mg/kg.

277 For obsessive-compulsive disorder, risperidone was associated with a 3.9-fold greater likel

278 As reported previously, discontinuation of risperidone was associated with a two- to fourfold incre

279 herapy for 4 to 8 months, discontinuation of risperidone was associated with an increased risk of rel

280 eatment of generalized anxiety disorder, and risperidone was associated with benefits in the treatmen

281 Risperidone was chosen as a model therapeutic and poly(l

282 After 4 weeks, the dosage of risperidone was increased to 2 mg/d in some cases.

283 The need for adjunctive risperidone was low and similar between groups (17% and

284 fective than quetiapine and ziprasidone, and risperidone was more effective than quetiapine.

285 and sertindole (-0.40; -0.74 to -0.04); and risperidone was more effective than sertindole (-0.32; -

286 Long-acting injectable risperidone was not superior to a psychiatrist's choice

287 f superiority for olanzapine, clozapine, and risperidone was seen in other efficacy outcomes, but res

288 whereas the recovery rates with inositol and risperidone were 17.4% and 4.6%, respectively.

289 ice treated with haloperidol, clozapine, and risperidone were assessed for locomotor activity and cat

290 Olanzapine and risperidone were associated with significantly greater w

291 Clinical outcomes with risperidone were equal to those with olanzapine, and res

292 han 0.5 and were stabilized on 3-6 mg/day of risperidone were randomly assigned to receive placebo (N

293 eatment dosage of olanzapine, quetiapine, or risperidone were randomly assigned to switch to ari-pipr

294 ted with good response to a 6-week course of risperidone, whereas pre-treatment VTA/midbrain connecti

295 benefit or a very small benefit, except for risperidone, which had a small-to-moderate effect on qua

296 administration of haloperidol and high-dose risperidone, which was most likely secondary to the seve

297 ividuals randomly assigned to olanzapine and risperidone who were continuing with their baseline medi

298 previously unavailable biomarker to indicate risperidone with a similar pharmacological mechanism, al

299 nd-generation antipsychotics (olanzapine and risperidone) with a first-generation antipsychotic (moli

300 F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozap